• If you are wondering whether Novo Nordisk stock is starting to look attractively priced or still carries a premium, the current setup offers plenty of clues in the recent numbers and news flow.
• The share price closed at US$47.42, with a 7 day gain of 8.9% and a 30 day gain of 5.5%, yet the stock is still down 9.5% year to date and has declined 30.7% over the past year and 35.7% over three years, while rising 22.0% over five years.
• Recent coverage around Novo Nordisk has focused on its role in the pharmaceuticals and biotech sector, with attention on how the company is positioned within its industry and broader healthcare themes. That context has given investors more information to weigh the recent share price moves against longer term expectations and perceived risks.
• Novo Nordisk currently has a valuation score of 5/6. This means it screens as undervalued on most of Simply Wall St's checks. The next sections will break down the key valuation methods used and will also highlight a more complete way to think about value at the end of the article.

Approach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Novo Nordisk could be worth by projecting its future cash flows and discounting them back to today, so you can compare that value with the current share price.

For Novo Nordisk, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The company’s last twelve months free cash flow is DKK 48.21b. Analyst and extrapolated estimates suggest free cash flow reaching DKK 96.90b by 2030, with a series of projected annual figures between 2026 and 2035 that are then discounted back to present value in DKK.

On this basis, the DCF model estimates an intrinsic value of US$93.31 per share, compared with the current share price of US$47.42. That gap implies the stock screens as 49.2% undervalued using these assumptions and projections.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 49.2%. Track this in your watchlist or portfolio, or discover 44 more high quality undervalued stocks.

Approach 2: Novo Nordisk Price vs Earnings

For a profitable company like Novo Nordisk, the P/E ratio is a straightforward way to think about value because it links the share price directly to the earnings that support it. In general, higher expected earnings growth and lower perceived risk can justify a higher P/E, while slower growth or higher risk usually support a lower, more conservative P/E level.

Novo Nordisk currently trades on a P/E of 11.18x. This sits below the Pharmaceuticals industry average P/E of 15.11x and below the peer group average of 23.71x. To go a step further, Simply Wall St calculates a proprietary “Fair Ratio” that estimates what P/E might be reasonable for Novo Nordisk given factors such as its earnings growth profile, profit margins, industry, market cap and risk indicators. This Fair Ratio is 22.02x.

The Fair Ratio aims to give a more tailored benchmark than a simple industry or peer comparison because it adjusts for company specific characteristics instead of assuming all stocks should trade on the same multiple. Comparing Novo Nordisk’s current P/E of 11.18x with the Fair Ratio of 22.02x indicates that the stock appears undervalued on this metric.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Novo Nordisk Narrative

Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St’s Community page you can use Narratives to attach your story about Novo Nordisk to the numbers by setting your own assumptions for future revenue, earnings and margins. You can then link that story to a forecast and a Fair Value, and instantly see how it compares with the current share price. The Narrative updates when new news or earnings arrive. For example, one investor might plug in a Fair Value of about US$102.97 per ADR based on stronger GLP 1 adoption, while another might use about US$95 based on more conservative growth and margins. Both can clearly see how their different views translate into different Fair Values and potential decisions about whether the stock looks cheap or expensive to them today.

Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.